Navigation Links
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Date:4/29/2009

lfa-2a) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in treatment-naive patients with genotype 1 chronic hepatitis C. As previously reported, Albuferon also met its primary endpoint in ACHIEVE 2/3, which was conducted in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C.

The results of both trials were presented on April 25 in the late-breaker session at the 44th annual meeting of the European Association for the Study of the Liver (EASL) in Copenhagen. The Phase 3 data demonstrate that, with half as many injections, in two pivotal Phase 3 trials, Albuferon achieved efficacy comparable to Pegasys with a positive safety profile. The submission of global marketing applications for Albuferon is planned in fall 2009, following discussions with the FDA and other regulatory authorities. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

LymphoStat-B(R) Phase 3 Results Expected in July and November 2009

HGS expects to report the first Phase 3 data for LymphoStat-B (belimumab) in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated in November 2009. BLISS-52 and BLISS-76 are the largest clinical trials ever conducted in lupus patients. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

$9 Million Milestone Payment Received from GSK Following Initiation of Phase 3 Development of Syncria(R)

HGS received a $9.0 million milestone payment during the first quarter of 2009, following GSK's initiation of a Phase 3 clinical trial program to evaluate Syncria (albiglutide) in the long-term treatment of type 2 diabetes mellitus. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled t
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014  MEI Pharma, ... on the clinical development of novel therapies for cancer, announced ... Chief Executive Officer, will present at BioCentury,s NewsMakers in ... at 8:30 a.m. Eastern time from the Millennium Broadway Hotel ... A live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... Oncothyreon Inc. (NASDAQ: ONTY ) today announced ... offerings of 10,000,000 shares of its Common Stock at ... for expected gross proceeds of $20 million and 10,000 ... a price to the public of $2,000.00 per share, ... of Series A Convertible Preferred Stock is non-voting and ...
(Date:9/18/2014)... , Sept. 18, 2014   Sigma-Aldrich ... today it has entered into a new gene ... Medical School,s Vector Core. Under the partnership, Sigma-Aldrich ... technology, experimental design consultation, and dedicated gene editing ... accelerate gene editing-based research at the U-M Medical ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... toward large-scale production -SWIFTWATER, Pa. and LYON, France, May ... sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ... A(H1N1) seed virus, enabling the world,s leading manufacturer of ... A(H1N1) vaccine. The emergence of a new influenza A(H1N1) ...
... CA, May 27, 2009 Senomyx, Inc. (Nasdaq: ... proprietary technologies to discover and develop novel flavor ingredients ... today the appointment of David L. Linemeyer, Ph.D., to ... than 20 years of experience in directing biology research ...
... atherosclerosis vaccine,development program by AFFiRiS AG is receiving ... project is being carried out in,cooperation with German ... is to increase the amount of "good" high ... reduce the occurrence of,harmful fatty deposits in the ...
Cached Biology Technology:Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine 2Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine 3SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 2SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY 3AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3
(Date:9/18/2014)... New research into the Crimean-Congo hemorrhagic fever virus ... disease in humans similar to that caused by Ebolavirus, ... This discovery has the potential to lead to novel ... , The research, reported in a paper published today ... by scientists at the Texas Biomedical Research Institute and ...
(Date:9/18/2014)... starts a "frequent flyers" program, fruit flies surely would ... has hosted increasing numbers of fruit fly research studies. ... in April, and another is scheduled launch to the ... launch in December. , Fruit flies are biomedical research ... space. Model organisms can reveal the basis for health ...
(Date:9/18/2014)... creatively manipulate spoken language is unique to humans. "The ... years of human evolution to make this possible are ... we now have," says Wolfgang Enard, Professor of Anthropology ... understand the molecular biological basis of language Enard has ... his latest study, undertaken in collaboration with scientists at ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... ants it's a way of life! Scientists at the University ... how to visually judge the height of horizontal barriers so ... Tobias Seidl will be presenting his latest research findings at ... Tuesday 4th April. , Desert ants generally scurry around at ...
... pups whose blubber falls below average levels may be at ... they get enough fat in their diets later on, according ... and presented at Experimental Biology 2006. , The study found ... the wild continued to gain weight and grow regardless of ...
... recently discovered cytokine to neural stem cells derived from ... Neurosurgical Institute have developed a tool to track and ... against their return. , Results of an animal study ... Cancer Research, and the researchers are now applying to ...
Cached Biology News:Alaska seal pup diet may hold key to decline of population 2Alaska seal pup diet may hold key to decline of population 3Alaska seal pup diet may hold key to decline of population 4Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 2Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection 3